On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
As many as two-thirds of glioblastoma patients don't respond to a central class of treatments due to a nifty DNA repair mechanism known as MGMT. DelMar Pharmaceuticals has a workaround that it hopes can extend the lives of patients in a meaningful way.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.